洛铂联合多西他赛治疗高危型HPV阳性中晚期宫颈癌的临床疗效及对血清CD105、VEGF、bFGF水平的影响  

Effect of lobaplatin combined with docetaxel as the treatment for high-risk HPV positive advanced cervical cancer and the influence on serum CD105,VEGF and bFGF levels

作　　者：朱丽娜 武文辉 党升强 郭愿愿 李强[2] ZHU Li’na;WU Wenhui;DANG Shengqiang;GUO Yuanyuan;LI Qiang(Department of Oncology,Chang’an Hospital,Xi’an 710016,Shaanxi,China;Department of Obstetrics and Gynecology,Nanjing Gulou Hospital Affiliated to Nanjing University,Nanjing 210000,Jiangsu,China)

机构地区：[1]长安医院肿瘤科,西安710016 [2]南京大学医学院附属南京鼓楼医院妇产科,南京2100000

出　　处：《癌症进展》2019年第21期2565-2568,共4页Oncology Progress

摘　　要：目的探讨洛铂联合多西他赛治疗高危型人乳头瘤病毒(HR-HPV)阳性中晚期宫颈癌的临床疗效及对血清CD105、血管内皮细胞生长因子(VEGF)及碱性成纤维细胞生长因子(bFGF)水平的影响。方法依据随机数字表法将208例HR-HPV阳性中晚期宫颈癌患者分为观察组(n=112)和对照组(n=96)。观察组患者采用洛铂联合多西他赛治疗,对照组患者采用顺铂联合多西他赛治疗。比较两组患者的临床疗效、血清细胞因子(CD105、VEGF、bFGF)水平及用药期间的不良反应发生情况。结果观察组和对照组患者的总有效率分别为88.39%(99/112)和81.25%(78/96),疾病控制率分别为95.54%(107/112)和91.67%(88/96),差异均无统计学意义(P﹥0.05)。治疗后,两组患者的血清CD105、VEGF、bFGF水平均较本组治疗前明显降低,差异均有统计学意义(P﹤0.01)。观察组患者治疗前后的CD105、VEGF、bFGF差值均明显高于对照组患者,差异均有统计学意义(P﹤0.01)。两组患者的不良反应主要表现为肾毒性、胃肠道反应及骨髓抑制,不良反应均较轻,多为1~2级,采用对症处理后症状均获得缓解。观察组患者的不良反应总发生率为87.50%(98/112),与对照组的85.42%(82/96)比较,差异无统计学意义(P﹥0.05)。结论洛铂联合多西他赛治疗HR-HPV阳性中晚期宫颈癌具有显著的治疗效果,且不良反应较轻,其作用机制可能与降低患者血清CD105、VEGF、bFGF水平有关,关于其临床应用,有待于进一步验证。Objective To investigate the effect of lobaplatin combined with docetaxel as the treatment for high-risk HPV(HR-HPV)positive advanced cervical cancer and the influence on the expression of serum CD105,vascular endothelial growth factor(VEGF)and basic fibroblast growth factor(bFGF).Method A random number table was used to stratify a cohort of 208 cases with HR-HPV positive advanced cervical cancer into study group(n=112)and control group(n=96),respectively.The study group was administered with lobaplatin combined with docetaxel,while the control group received cisplatin plus docetaxel,respectively.The clinical efficacy,serum cytokines(CD105,VEGF and bFGF)levels and adverse drug reactions during treatment were observed and compared between the two groups.Result The overall response rates(ORR)of the two groups were 88.39%(99/112)and 81.25%(78/96),and disease control rates(DCR)were 95.54%(107/112)and 91.67%(88/96),respectively,the differences were of statistical significance(P>0.05).After treatment,the serum levels of CD105,VEGF and bFGF were significantly decreased in both groups as compared with that before treatment(P<0.01).The differences of serum CD105,VEGF and bFGF levels in study group before and after treatment were significantly higher compared to control group(P<0.01).The main adverse reactions in the two groups were renal toxicity,gastrointestinal reactions and bone marrow suppression,which were generally mild at grade 1 to 2,and were relieved after symptomatic treatment.The overall incidence of adverse reactions in study group was 87.50%(98/112),and was similar to the 85.42%(82/96)in control group,indicating no statistical significance(P>0.05).Conclusion The combined regimen of lobaplatin plus docetaxel is therapeutically effective in the treatment of HR-HPV positive advanced cervical cancer,inducing mild adverse reactions,moreover,the underlying mechanism is likely to be associated with reduced serum levels of CD105,VEGF,and bFGF,however the clinical application shall be further validated.

关 键 词：洛铂 HPV阳性 宫颈癌 细胞因子 

分 类 号：R737.33[医药卫生—肿瘤]